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Edited by Laszlo NagyAbstract TNF-a acts on the hypothalamus modulating food in-
take and energy expenditure through mechanisms incompletely
elucidated. Here, we explore the hypothesis that, to modulate
insulin-induced anorexigenic signaling in hypothalamus, TNF-a
requires the synthesis of NO. TNF-a activates signal transduc-
tion through JNK and p38 in hypothalamus, peaking at
108 M. This is accompanied by the induction of expression of
the inducible and neuronal forms of NOS, in both cases peaking
at 1012 M. In addition, TNF-a stimulates NOS catalytic activ-
ity. Pre-treatment with TNF-a at a low dose (1012 M) inhibits
insulin-dependent anorexigenic signaling, and this eﬀect is abol-
ished in iNOS but not in nNOS knockout mice.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Tumor necrosis factor-a (TNF-a) is one of the mediators of
the hypothalamic anorexigenic signals that participate in the
induction of the cachexia syndromes present in advanced stage
cancer and in severe infectious diseases [1,2]. The mechanisms
involved in TNF-a-dependent modulation of food intake and
energy expenditure are poorly characterized but may involve
the control of hypothalamic neurotransmitter expression
[3,4], in situ stimulation of the expression of other cytokines,
particularly IL-1b [5,6], and the activation of anorexigenic lep-
tin-like signal transduction in the hypothalamus [7].
In addition, TNF-a and other pro-inﬂammatory proteins
produced by the adipose tissue during obesity participate in
the genesis of peripheral insulin resistance by activating serine
kinases that hamper insulin signal transduction through the
IRS proteins [8]. Based on this fact, it has been proposed that
the adipokines act as a mechanistic link between obesity and
type 2 diabetes mellitus. This suspicion was enforced by recentAbbreviations: iNOS, inducible nitric oxide synthase; NO, nitric oxide;
NOS, nitric oxide synthase; nNOS, neuronal nitric oxide synthase;
TNF-a, tumor necrosis factor-alpha
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doi:10.1016/j.febslet.2006.07.042studies showing that: (a) the consumption of a high fat diet,
which is, per se, one of the most important environmental fac-
tors leading to obesity, induces the hypothalamic expression of
pro-inﬂammatory cytokines, such as TNF-a, IL-1b and IL-6,
and inhibits insulin and leptin signaling through intracellular
mechanisms related to inﬂammatory signal transduction [9–
11]; and (b) acute TNF-a treatment increases the sequestration
of insulin by the brain [12]. As a consequence, the anorexigenic
eﬀects of both hormones may be stalled, predisposing to obes-
ity.
In this context, we can assume that TNF-a and other cyto-
kines play important roles in the control of body energy stores.
In some cases they favor energy depletion, whilst in other cases
they favor the increase in body fat. Much of these eﬀects seem
to depend on cytokine signaling in the hypothalamus.
In peripheral tissues and in isolated astrocytes, TNF-a is
capable of promoting nitric oxide (NO) production mostly
through the activation of expression of the inducible nitric
oxide synthase (iNOS) [13–15]. Since NO, acting in the hypo-
thalamus, is reported to be a modulator of food intake [16,17],
we hypothesized that, in order to modulate insulin action in
hypothalamus, TNF-a requires the activation of NOS and
the synthesis of NO. Therefore, we decided to evaluate the par-
ticipation of the inducible and neuronal forms of NOS on
TNF-a-dependent modulation of food intake.2. Materials and methods
2.1. Antibodies, chemicals and buﬀers
Reagents for SDS–polyacrylamide gel electrophoresis (SDS–PAGE)
and immunoblotting were from Bio-Rad (Richmond, CA, USA).
HEPES, phenylmethylsulfonyl ﬂuoride, aprotinin, dithiothreitol, Tri-
ton X-100, Tween 20, glycerol, bovine serum albumin (fraction V),
Nx-Nitro-L-arginine methyl ester hydrochloride (L-NAME), and
angiotensin II were from Sigma (St. Louis, MO, USA). Protein A-Se-
pharose 6MB was from Pharmacia (Uppsala, Sweden), 125I-protein A
was from ICN Biomedicals (Costa Mesa, CA, USA), and nitrocellu-
lose paper (BA85, 0.2 lm) was from Amersham (Aylesbury, UK). So-
dium thiopental (Amytal) and human recombinant insulin (Humulin
R) were from Lilly (Indianapolis, IN, USA). For determination of
NOS activity, silica gel thin layer chromatographic plates were
obtained from the Fisher Chemical Company (Pittsburg, PA, USA).
b-NADPH,5,6,7,8-tetrahydrobiopterin dihydrochloride, NP40, pep-
statin, arginase inhibitor [S-(+)-2-amino-S-(iodocetamido) pentanoic
acid], calmodulin, iodocetamide, EDTA, and niacinamide were ob-
tained from Calbiochem (Darmstadt, Germany). 14C-L-arginine
(300 mCi/mmol, 100 lCi/ml) was obtained from Amersham (Ayles-
bury, UK). Mouse recombinant TNF-a was from Calbiochem.blished by Elsevier B.V. All rights reserved.
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lated at Thr 183 and Tyr 185, sc-6254), phospho-p38 (mouse monoclo-
nal, recognizing p38 phosphorylated at Tyr 182, sc-7973), c-Fos (rabbit
polyclonal, sc-7202), c-Jun (rabbit polyclonal, sc-1694), nNOS (rabbit
polyclonal, sc-8309), and iNOS (mouse monoclonal, sc-7271) antibod-
ies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz,
CA, USA). Anti-phospho-Akt (rabbit polyclonal, recognizing Akt
phosphorylated at Ser 473, #05-736) was purchased from Upstate Bio-
technology (Charlottesville, VA, USA) and phospho-FKHR (FOXO1-
rabbit polyclonal, recognizing FOXO1 phosphorylated at Ser 256,
#9461) was purchased from Cell Signaling Technology (Danvers,
MA, USA).
2.2. Experimental animals
Eight-week-old (280–300 g) male Wistar rats (Rattus norvegicus)
and the iNOS knockout mice and their respective wild type control
(C57Bl/6 J) (25–30 g) were from the University of Campinas Central
Animal Breeding Center. The neuronal nitric oxide synthase (nNOS)
knockout mice and their respective wild type control (C57Bl/6J) were
from a breeding colony established at Tropical Medicine Institute,
Univestity of Sa˜o Paulo. The iNOS knockout mice founders were pur-
chased from the Jackson Laboratory and are derived originally from
the colony established at the University of Virginia [18]. The nNOS
knockout mice were kindly donated by Ted M. Dawson from the
Johns Hopkins University [19] and were produced by homologous
recombination, as originally described [20]. The experimental animals
were maintained on a 12 h-light/dark cycle and allowed ad libitum ac-
cess to standard rodent chow and water. Food was withdrawn 6 h be-
fore the experiments. All experiments were conducted in accord with
the principles and procedures described by the NIH Guidelines
for the Care and Use of Experimental Animals and were approved
by the State University of Campinas Ethical Committee.
2.3. ICV cannulation
Rats and mice were stereotaxically instrumented using a Stoelting
stereotaxic apparatus, according to a method previously described
[21]. The correct location of the cannula was tested one week after can-
nulation by the evaluation of the drinking response elicited by ICV
angiotensin II [22]. Stereotaxic coordinates were: antero-posterior
0.2 mm/lateral 1.5 mm/depth 4.0 mm for rats; and antero-posterior
0.15 mm/lateral 0.7 mm/depth 2.2 mm for mice.
2.4. Protocol for food ingestion determination
ICV cannulated rats were food deprived for 6 h (from 12 to 18 h)
and at 18 h were ICV treated with insulin (2.0 ll, 106 M), TNF-a
(2.0 ll, 106, 108, 1010, 1012, 1014 M), or saline (2.0 ll). Food
ingestion was determined over the next 12 h. ICV cannulated mice
were food deprived for 6 h. At 18 h, mice were treated with insulin
(1.0 ll, 106 M), TNF-a (108 and 1012 M), L-NAME (1.0 ll,
108 M) or saline. Food ingestion was determined over the next
12 h. Mice were also evaluated for mean daily spontaneous food in-
take. For this, non-ICV-cannulated mice were placed in metabolic
cages and food intake was determined daily at 8 h. For each animal
the determinations were performed for four consecutive days. Food in-
take was always determined as the diﬀerence between the amounts of
chow oﬀered (40 g for rats and 20 g for mice) and the remains, includ-
ing spillage.
2.5. Tissue extraction, immunoblotting and immunoprecipitation
ICV cannulated rats and mice were anesthetized and acutely treated
with saline (2.0 ll), insulin or TNF-a. After 5–180 min, according to
each experiment, the hypothalami were dissected and immediately
homogenized in solubilization buﬀer at 4 C [1% Triton X-100,
100 mM Tris–HCl (pH 7.4), 100 mM sodium pyrophosphate,
100 mM sodium ﬂuoride, 10 mM EDTA, 10 mM sodium orthovana-
date, 2.0 mM PMSF and 0.1 mg aprotinin/ml] with a Polytron PTA
20 S generator (model PT 10/35; Brinkmann Instruments, Westbury,
NY, USA). Insoluble material was removed by centrifugation for
20 min at 9000 · g in a 70.Ti rotor (Beckman, Fullerton, CA, USA)
at 4 C. The protein concentration of the supernatants was determined
by the Bradford dye binding method. Aliquots of the resulting super-
natants containing 2.0 mg of total protein were used for immunopre-
cipitation with antibodies against c-Fos at 4 C overnight, followedby SDS–PAGE, transfer to nitrocellulose membranes and blotting
with anti-c-Jun. In direct immunoblot experiments, 0.2 mg of protein
extracts were separated by SDS–PAGE, transferred to nitrocellu-
lose membranes and blotted with anti-phospho-JNK, phospho-p38,
c-Fos, c-Jun, iNOS, nNOS, phospho-Akt and phospho-FKHR
(FOXO1) antibodies.
2.6. Quantiﬁcation of NOS activity
As previously described [23,24], the hypothalami from Wistar rats
were homogenized in phosphate-buﬀered-saline (PBS) (PBS–isotonic
PBS, pH 7.4), containing 1% NP40, 2.0 mM PMSF, 1.0 lM pepstatin,
20 mM EDTA, 3.7 mg/ml iodocetamide. The samples were left on ice
for 30 min and spun for 20 min at 20000 · g in a micro centrifuge. The
crude supernatant was aspirated and protein was estimated using a
Detergent Compatible protein assay from BioRad Laboratories (Her-
cules, CA, USA). For each NOS assay, 30 lg of sample from the tissue
extracts was added to the reaction mixture (50 ll), which consisted of
33.3 mM PIPES-NaOH, pH 7.0, 0.12 mM NADPH, 0.4 mM CaCl2,
0.33 lg/ml calmodulin, 0.33 mM DTT, 0.33 mM EDTA, 1.0 mM nia-
cinamide, 50 lM tetrahydrobiopterin, 0.17 mg/ml arginase inhibitor
and 0.15 ll of 14C-L-arginine. The incubation was carried out at
37 C for speciﬁed time periods. The NOS reaction was terminated
by adding 2.5 vol. of cold methanol. The samples were left on ice for
20 min and centrifuged at 20000 · g for 10 min using a microcentri-
fuge. The liquid was then directly spotted onto a silica gel TCL plate,
air dried, and subjected to chromatography. For this, the solvent used
was ammonium hydroxide:chloroform:methanol:water (2:0.5:4.5:1).
Chromatography was performed until the solvent front reached at
least 10 cm from the origin. After chromatography, the radioactivity
in the TCL plates was counted using a radioactivity scanner. The
amount of 14C citrulline that corresponded to each of the samples
was counted and compared with that of the zero time point.
2.7. Statistical analysis
Speciﬁc protein bands present in the blots were quantiﬁed by densi-
tometry. Mean values ± S.E.M. obtained from densitometric scans and
means ± S.E.M. values for all remaining parameters evaluated in the
study were compared utilizing Student’s t-test for paired samples or
by repeat-measure analysis of variance (one-way or two-way ANOVA)
followed by post hoc analysis of signiﬁcance (Bonferroni test) when
appropriate. A P < 0.05 was accepted as statistically signiﬁcant.3. Results and discussion
The cytokine TNF-a acts through at least two distinct recep-
tors, TNF-R1 and TNF-R2 [25]. TNF-R2 is expressed mostly
in cells of the immune system and is thought to play an impor-
tant role in the ontogenesis and diﬀerentiation of lymphoid tis-
sues [25], whilst TNF-R1 is widely distributed and mediates
TNF-a signaling towards activation of pro-inﬂammatory re-
sponses, control of gene expression, regulation of apoptosis,
and production of NO, amongst a number of other functions
[26]. Both types of receptors have been found in the central
nervous system, including the hypothalamus [27]. However, lit-
tle is known about their speciﬁc functions in this site. In fact,
no previous study has evaluated the capacity of TNF-a to acti-
vate pro-inﬂammatory signal transduction in the hypothala-
mus of rodents. Therefore, we started by determining the
time-course and dose-response eﬀects of ICV injected TNF-a
upon JNK and p38 signaling, two of the most important path-
ways activated by TNF-a. As shown in Fig. 1A, TNF-a in-
duces the phosphorylation-activation of JNK, starting at
5 min and reaching a peak at 10 min. This eﬀect was already
detected at a dose as low as 1010 M and reached a peak at
108 M (Fig. 1B). In addition, TNF-a induced the phosphory-
lation-activation of p38, peaking at 10 min (Fig. 1C). These ef-
fects were accompanied by a time dependent induction of the
Fig. 1. TNF-a signal transduction in hypothalamus. Anesthetized rats were ICV treated with 2.0 ll, 108 M TNF-a (A, C–F) or at the
concentrations depicted in the ﬁgure. (B) After the time frames, as depicted in the ﬁgures (A, C–F) or after 10 min (B), hypothalami were obtained for
protein extract preparation. For direct immunoblot analysis (A–C, E, F), samples containing 0.2 mg protein were separated by SDS–PAGE,
transferred to nitrocellulose membranes and blotted (IB) with speciﬁc antibodies to phospho-JNK (p-JNK) (A,B); phospho-p38 (p-p38) (C); c-Fos
(E) and c-Jun (F). For immunoprecipitation followed by immunoblot, samples containing 2.0 mg total protein were submitted to immunopre-
cipitation (IP) with antibodies to c-Fos (D); immunoprecipitates were collected with Protein A-Sepharose and separated by SDS–PAGE, transferred
to nitrocellulose membranes and blotted with antibodies to c-Jun. Speciﬁc bands were quantiﬁed by densitometric analysis. In all experiments, n = 4;
*P < 0.05 vs. time 0 (A, C–F) or vs. concentration 0 (B). Results are presented as means ± S.E.M.
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maintained for at least 15 min (Fig. 1D). Finally, the eﬀects
of TNF-a resulted in the induction of expression of c-Fos, de-
tected at 60 min (Fig. 1E) and of c-Jun, detected at 15 min
(Fig. 1F), and lasting for at least 60 min.
Next, we evaluated the capacity of TNF-a to induce the cat-
alytic activity of NOS in hypothalamus. Although TNF-a
dependent activation of NOS activity has been widely charac-
terized in peripheral tissues [14,28], no previous study has
examined this property in the hypothalamus. For this, rats
were ICV cannulated and treated with 2.0 ll, 10 8 M TNF-
a. Hypothalami were obtained at 0, 10 and 30 min and sampleswere prepared for determination of NOS activity using a chro-
matographic method that allows the measurement of citrulline
production. As shown in Fig. 2, TNF-a was capable of rapidly
inducing the catalytic activity of NOS, which was already de-
tected at 10 min and was still present at 30 min. In other tis-
sues, the ability of TNF-a to induce NOS activity is directly
related to its capacity to induce the expression of NOS iso-
forms, mostly iNOS [14,15,28,29]. Therefore, we employed
an immunoblot assay, with isoform-speciﬁc antibodies, to
evaluate the eﬀect of TNF-a on the hypothalamic expression of
nNOS and iNOS. As depicted in Figs. 3A and B, both low
dose (1012 M) and high dose (108 M) TNF-a, respectively,
Fig. 2. TNF-a – induced activation of nitric oxide synthase catalytic
activity. Anesthetized rats were ICV treated with 2.0 ll, 108 M TNF-
a. After the time points depicted in the ﬁgure, the hypothalami were
obtained for extract preparation. The reaction was carried out as
described under Section 2. Citrulline was separated by TLC and the
radioactivity in the TCL plates was counted using a radioactivity
scanner. The amount of 14C citrulline that corresponded to each of the
samples was counted and compared with the zero time point. Results
are presented as means ± S.E.M.; n = 4; *P < 0.05 vs. time 0 min.
4628 J.C. Moraes et al. / FEBS Letters 580 (2006) 4625–4631are capable of inducing the rapid expression of nNOS in this
anatomical territory. In both cases, signiﬁcant increases of
the amount of nNOS protein were detected at 10 min and were
still present at 120 min. Interestingly, the greatest eﬀect of
TNF-a upon mean hypothalamic nNOS expression was ob-
tained with the dose of 1012 M (Fig. 3C). Similarly, TNF-aFig. 3. Induction of nNOS and iNOS expression by TNF-a. Anesthetized ra
TNF-a or at the concentrations depicted in the ﬁgures (C and F). After the tim
F), hypothalami were obtained for protein extract preparation. Samples con
nitrocellulose membranes and blotted (IB) with speciﬁc antibodies to nNOS
analysis. In all experiments, n = 4; *P < 0.05 vs. time 0 (A, B, D and E) or vwas also capable of inducing the expression of iNOS in hypo-
thalamus. This phenomenon was detected using either a low
(1012 M) (Fig. 3D) or a high (108 M) (Fig. 3E) dose of
TNF-a, and was somewhat delayed as compared with the
expression of nNOS, starting only at 30 min and lasting for
at least 120 min. As for iNOS, the greatest eﬀect of TNF-a
on mean hypothalamic level of nNOS occurred with a dose
of 1012 M (Fig. 3F).
Since TNF-a is capable of inducing the expression and activ-
ity of NOS, and considering that NO has a considerable eﬀect
on food intake [30–32], we decided to evaluate whether, at least
part of the modulatory eﬀect exerted by TNF-a on the hypo-
thalamic insulin action on feeding would depend on the activa-
tion of NOS. First, we determined the eﬀect of a previous dose
of TNF-a on insulin-inhibited food intake. For this, rats were
ICV cannulated and after the recovery period, were treated
with saline, insulin alone, 1012 M TNF-a alone, 108 M
TNF-a alone, 1012 M TNF-a followed by insulin, or
108 M TNF-a followed by insulin. Previous studies have
shown that insulin, acutely injected in the hypothalamus, pro-
motes a potent inhibition of food intake of about 35–50%
[21,33,34]. As shown in Fig. 4A, in this study we observed a
reduction of 45% on food intake promoted by insulin. TNF-
a at the concentration of 1012 M exerted no eﬀect on food in-
take, whilst at the dose of 108 M led to a reduction of 20% on
food intake. Interestingly, the pre-treatment with 1012 M
TNF-a produced an inhibitory eﬀect on insulin action suchts were ICV treated with 2.0 ll, 1012 M (A and D), 108 M (B and E)
e points depicted in the ﬁgures (A, B, D and E) or after 30 min (C and
taining 0.2 mg protein were separated by SDS–PAGE, transferred to
(A–C) or iNOS (D–F). Speciﬁc bands were quantiﬁed by densitometric
s. concentration 0 (C and F). Results are presented as means ± S.E.M.
Fig. 4. Role played by NOS isoforms in the control of food intake and insulin signal transduction. Twelve-hours food intake determination was
performed in ICV cannulated Wistar rats (A), C57Bl/6 (WT) mice (B), nNOS knockout mice (D) and iNOS knockout mice (E). For this, animals
were food deprived from 12 to 18 h and then treated with saline (S), insulin (I) (106 M), TNF-a (T) (1012 or 108 M), L-NAME (L) (108 M),
insulin (106 M) plus TNF-a (1012 or 108 M) or L-NAME (108 M) plus insulin (106 M) plus TNF-a (1012 or 108 M) (volumes were 2.0 ll for
rats and 1.0 ll for mice). Food was reintroduced and spontaneous ingestion was determined over the next 12 h. Twenty-four hours spontaneous food
intake was determined for C57Bl/6 (WT), nNOS knockout mice and iNOS knockout mice (C). Insulin signal transduction towards Akt (F) and
FOXO1 (G) was determined in C57Bl/6 (WT), nNOS knockout mice and iNOS knockout mice. For this, anesthetized mice were ICV treated with
1.0 lL saline (), 106 M insulin (+) or 1012 M TNF-a plus insulin (++) and, after 10 min, hypothalami were obtained for protein extract
preparation. Samples containing 0.2 mg protein were separated by SDS–PAGE, transferred to nitrocellulose membranes and blotted (IB) with
speciﬁc antibodies to phospho-Ser473 Akt (F) or phospho-Ser256 FOXO1 (G). Speciﬁc bands were quantiﬁed by densitometric analysis. In all
experiments, n = 4. In A–E, *P < 0.05 vs. saline treated (S); § P < 0.05 vs. insulin treated (I). In F and G, *P < 0.05; n.s., not signiﬁcant. Results are
presented as means ± S.E.M.
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Finally, the pre-treatment with 108 M TNF-a produced no
eﬀect on the hypothalamic action of insulin on feeding. To
evaluate if the pharmacological inhibition of NOS would exert
any modulatory eﬀect on TNF-a dependent control of insulin
action on feeding, C57Bl/6J mice were ICV pre-treated with L-
NAME and then treated with TNF-a and insulin. As depicted
in Fig. 4B, L-NAME completely abolished the inhibitory eﬀect
of TNF-a 1012 M upon insulin-inhibited food intake, suggest-
ing that most of the eﬀect of this dose of TNF-a on insulin ac-tion is mediated through NOS. Next, to examine the
participation of the NOS isoforms in TNF-a dependent mod-
ulation of the insulin action on feeding we used knockout mice
for the nNOS and iNOS isoforms. The mean daily food in-
takes of the knockout strains were not diﬀerent from that of
the control (Fig. 4C). In addition, in all three strains of mice
analyzed (C57Bl/6J, nNOS knockout and iNOS knockout)
insulin exerted a similar eﬀect on food intake, promoting an
inhibition of approximately 50% (Fig. 4B, D and E). With
regard to the eﬀects of the pre-treatment with TNF-a on the
4630 J.C. Moraes et al. / FEBS Letters 580 (2006) 4625–4631action of insulin on feeding, control and nNOS knockout mice
had similar responses, presenting results proportional to those
seen in rats. Thus, 1012 M TNF-a inhibited, while 108 M
TNF-a exerted no eﬀect on insulin action (Figs. 4B and D).
However, in iNOS knockout mice the results were contrasting.
In these mice, the pre-treatment with 1012 M TNF-a exerted
no inhibitory eﬀect on the insulin action on food intake
(Fig. 4E). In addition, the pre-treatment with 108 M TNF-a
enhanced the inhibitory eﬀect of insulin (Fig. 4E).
Finally, to determine whether the transduction of the hypo-
thalamic insulin signal towards Akt and FOXO1 would be
somehow modiﬁed in NOS isoform speciﬁc knockout mice,
ICV cannulated mice were treated with saline or insulin and
protein extracts obtained from hypothalami were employed
in immunoblot experiments. As shown in Fig. 4F and G, no
diﬀerences in insulin-stimulated phosphorylation of Akt and
FOXO1 were detected in nNOS and iNOS knockout mice as
compared with control. In iNOS knockout mice, the basal
phosphorylation state of both Akt and FOXO1 were higher
than in control and nNOS knockout mice. However, upon
pre-treatment with TNF-a, control and nNOS knockout mice
presented a signiﬁcant inhibition of insulin-induced phosphor-
ylation of Akt and FOXO1, a phenomenon not observed in
iNOS knockout mice (Fig. 4G and F).
As a whole, this study shows that TNF-a is capable of acti-
vating signal transduction through pro-inﬂammatory path-
ways in the hypothalamus. In addition, TNF-a is
demonstrated to be capable of activating nNOS and iNOS
protein expression in hypothalamus, which is accompanied
by increased NOS catalytic activity. The optimal dose for
TNF-a to activate signal transduction through JNK is some-
what higher than the optimal dose required for induction of
expression of the NOS isoforms, suggesting that the TNF-a-in-
duced expression of iNOS and nNOS occurs though a pathway
other than JNK. The pathways used by TNF-a to induce NOS
expression and activity are controversial. Initially it was sug-
gested that cytokines, including TNF-a, regulate NOS activity
only by controlling the intracellular levels of tetrahydrobiop-
terin [35]. However, it was later seen that TNF-a can also con-
trol iNOS gene expression through protein tyrosine kinase
signal transduction [36]. More recently, the participation of
p38 in the TNF-a-induced expression of iNOS was suggested
by indirect methods [37]. Interestingly, the eﬀect of TNF-a
upon food intake is also dose dependent. When acting alone,
a high dose of TNF-a inhibits food intake, while no regulation
is produced by a low dose. Conversely, only a low dose of
TNF-a is capable of hampering the eﬀect of insulin on feeding.
The defective expression of iNOS, but not of nNOS, com-
pletely abolishes the eﬀect of TNF-a upon insulin action. This
phenomenon is independent of the modulation of insulin sig-
nal transduction through Akt and FOXO1.
Taken together, the results of this investigation and of previ-
ous studies [1–3,9] suggest that TNF-a acts in the hypothala-
mus inhibiting food intake by its own, and blunting insulin-
induced anorexigenic signal. These diverse eﬀects are depen-
dent on TNF-a local concentrations. The reason why TNF-a
interacts with insulin action in the hypothalamus is still un-
clear. In peripheral tissues, this phenomenon has been widely
studied and is thought to play an important role in insulin
resistance [8]. Conversely, in hypothalamus, the interaction be-
tween TNF-a and insulin is poorly characterized but it seems
to occur through at least two diﬀerent mechanisms; intracellu-lar cross-talk [9–11] and modulation of insulin availability [12].
At high level, TNF-a stimulates canonical pro-inﬂammatory
signal transduction, which is accompanied by an inhibitory ef-
fect on food intake. This eﬀect is not incremented by insulin.
On the other hand, at low level there is no eﬀect of TNF-a
upon classical pro-inﬂammatory signaling but there is a
remarkable eﬀect on NOS isoforms expression and on NOS
activity. This is accompanied by an inhibitory eﬀect on hypo-
thalamic insulin action, but by no independent eﬀect on food
intake. At this point we are unable to deﬁne if the eﬀects herein
reported are solely due to an increased local production of NO
or are dependent on the presence of NO-derived metabolites
such as peroxynitrite, as reported in other experimental condi-
tion of inﬂammation in the central nervous system [38]. Never-
theless, since no regulation of insulin signal transduction was
seen in iNOS deﬁcient mice we suspect that the NO produced
by iNOS in response to TNF-a confronts the action of insulin
through a direct eﬀect on neurotransmitter production or re-
lease. In this regard, it has been previously shown that NO
may impair hypothalamic serotonin release and increase dopa-
minergic activity, both leading to the modulation of food in-
take [30–32]. In addition, it has been shown that iNOS
deﬁcient mice are primarily hypoleptinemic, which also, could
contribute to explain the phenomena herein described [39]. Fi-
nally, in the presence of pro-inﬂammatory activation, such as
during high dose TNF-a stimulation, the inhibitory eﬀect on
insulin action is lost probably due to the engagement of mech-
anisms that have not been completely elucidated, which partic-
ipate in the classical anorexigenic eﬀects of this cytokine [1,2].
Therefore, we conclude that TNF-a exerts distinct eﬀects on
hypothalamic control of feeding. These eﬀects are dependent,
at least in part, on the activation of iNOS and on the induction
of classical intracellular inﬂammatory signaling. Although this
is still a debated matter, the results of this work provide further
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